| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | MAD2; HSMAD2 |
| WB Predicted band size | 24 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human MAD2L1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MAD2L1抗体的3篇代表性文献概览：
---
1. **文献名称**：**"MAD2L1 overexpression predicts poor prognosis in colorectal cancer and promotes genomic instability"**
**作者**：Li et al.
**摘要**：本研究通过免疫组化(使用MAD2L1特异性抗体)检测结直肠癌组织中MAD2L1蛋白表达，发现其过表达与肿瘤分期和患者生存率显著相关。实验表明MAD2L1异常表达导致染色体不稳定性，可能成为预后标志物。
2. **文献名称**：**"Validation of a novel anti-MAD2L1 antibody for functional analysis of the mitotic checkpoint"**
**作者**：Kienitz et al.
**摘要**：文章验证了一种高特异性MAD2L1抗体的应用，通过Western blot和免疫荧光证实其在HeLa细胞中检测内源性MAD2L1的可靠性，并证明MAD2L1缺失会破坏纺锤体检查点功能，导致早熟染色体分离。
3. **文献名称**：**"Targeting MAD2L1 in triple-negative breast cancer: therapeutic implications of checkpoint silencing"**
**作者**：Wang et al.
**摘要**：研究利用MAD2L1抗体评估其在三阴性乳腺癌中的表达水平，结合RNA干扰技术发现抑制MAD2L1可增强紫杉醇化疗敏感性，提示其作为联合治疗靶点的潜力。
---
这些文献涵盖了MAD2L1抗体在疾病机制、实验验证及临床转化中的应用，为相关研究提供了技术及理论参考。如需具体文献来源，建议通过PubMed或Web of Science检索标题或作者进一步获取全文。
MAD2L1 (Mitotic Arrest Deficient 2-Like 1) is a critical component of the mitotic spindle assembly checkpoint (SAC), a surveillance mechanism ensuring accurate chromosome segregation during cell division. This protein acts as a sensor of unattached kinetochores, delaying anaphase onset until all chromosomes are properly aligned. Dysregulation of MAD2L1 is linked to chromosomal instability, a hallmark of cancer and genetic disorders.
MAD2L1 antibodies are essential tools for studying SAC function, protein localization, and expression dynamics in mitotic processes. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate MAD2L1’s role in cancer progression, drug resistance, and response to anti-mitotic therapies. Elevated MAD2L1 levels are observed in various cancers (e.g., breast, lung, colorectal), correlating with poor prognosis, while reduced expression may impair checkpoint signaling, promoting aneuploidy.
These antibodies also aid in exploring MAD2L1’s interaction with other checkpoint proteins (e.g., BUBR1. CDC20) and its involvement in pathological conditions beyond cancer, such as autoimmune diseases and neurodegeneration. Researchers utilize MAD2L1-targeting antibodies to validate experimental models (e.g., knockout cells) and assess therapeutic interventions targeting mitotic checkpoints.
×
